In Re Des Litigation. Deborah Ashley and Andrew Ashley v. Boehringer Ingelheim Pharmaceuticals

7 F.3d 20, 1993 U.S. App. LEXIS 25692
CourtCourt of Appeals for the Second Circuit
DecidedOctober 4, 1993
Docket1271, Docket 92-9074
StatusPublished
Cited by49 cases

This text of 7 F.3d 20 (In Re Des Litigation. Deborah Ashley and Andrew Ashley v. Boehringer Ingelheim Pharmaceuticals) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Des Litigation. Deborah Ashley and Andrew Ashley v. Boehringer Ingelheim Pharmaceuticals, 7 F.3d 20, 1993 U.S. App. LEXIS 25692 (2d Cir. 1993).

Opinion

JON 0. NEWMAN, Chief Judge:

This appeal primarily concerns the ability of a party that prevails on the merits to obtain appellate review of adverse interlocutory rulings. The issue arises on the appeal of defendant Boehringer Ingelheim Pharmaceuticals (“Boehringer”) from the September 14, 1992, judgment of the District Court for the Eastern District of New York (Jack B. Weinstein, Judge) dismissing with prejudice the complaint of Debra and Andrew Ashley. Boehringer, the successor to a California manufacturer of diethylstilbestrol (“DES”), hopes by this appeal to challenge the District Court’s April 13, 1992, interlocutory order that (a) upheld personal jurisdiction over Boehringer in New York and (b) applied to Boehringer New York substantive law on DES liability. In re DES Cases, 789 F.Supp. 552 (E.D.N.Y.1992). Boehringer contends that these rulings are unconstitutional or constitute erroneous interpretations of New York law. We conclude that the general rule prohibiting a prevailing party from appealing applies to this case,' and dismiss the appeal.

Background

Some background information concerning DES and the varying approaches to DES liability adopted by different states will assist in understanding Boehringer’s motivation in attempting to appeal from the interlocutory rulings. Between 1941 and 1971, approximately 300 pharmaceutical companies marketed DES, a synthetic form of estrogen, for the prevention of miscarriages. In 1971, the FDA banned DES after determining that the drug caused vaginal adenocarcinoma, a form of cancer, and adenosis, a precancerous vaginal or cervical growth, in the daughters of women who took the drug. Although it was made in pills of different shapes and colors, all DES was chemically identical, and druggists generally filled prescriptions from whatever stock they had on hand. Most women ingesting DES did not know the identity of the manufacturer, and by the time their daughters realized they had been injured by DES, it was often impossible to determine the manufacturer.

Faced with this situation, the California Supreme Court adopted a “market share” *22 theory of liability. See Sindell v. Abbot Laboratories, 26 Cal.3d 588, 163 Cal.Rptr. 132, 607 P.2d 924, cert. denied, 449 U.S. 912, 101 S.Ct. 285, 66 L.Ed.2d 140 (1980). The Court held that a plaintiff could recover by showing that her injuries had been caused by DES and by joining as defendants “the manufacturers of a substantial share of the DES which her mother might have taken.” Id. at 612, 163 Cal.Rptr. at 145, 607 P.2d at 937. Each manufacturer would “be held liable for the proportion of the judgment represented by its share of [the] market unless it demonstrates that it could not have made the product which caused plaintiffs injuries.” Id. In a later case, the California Court clarified that liability was several only, with the consequence that if less than all manufacturers are joined, a plaintiff will recover less than 100 percent of her damages. See Brown v. Superior Court (Abbott Laboratories), 44 Cal.3d 1049, 245 Cal.Rptr. 412, 751 P.2d 470 (1988).

The New York Court of Appeals substantially adopted the Sindell approach. See Hymowitz v. Eli Lilly and Co., 73 N.Y.2d 487, 541 N.Y.S.2d 941, 539 N.E.2d 1069, cert. denied, 493 U.S. 944, 110 S.Ct. 350, 107 L.Ed.2d 338 (1989). However, the Court of Appeals altered the Sindell approach in one significant respect, limiting a defendant’s opportunity to exculpate itself from liability by showing that it could not have caused the plaintiffs injuries:

To be sure, a defendant cannot be held liable if it did not participate in the marketing of DES for pregnancy use; if a DES producer satisfies its burden of proof of showing that it was not a member of the market of DES sold for pregnancy use, disallowing exculpation would be unfair and unjust. Nevertheless, because liability here is based on the over-all risk produced, and not causation in a single case, there should be no exculpation of a defendant who, although a member of the market producing DES for pregnancy use, appears not to have caused a particular plaintiffs injury. It is merely a windfall for a producer to escape liability solely because it manufactured a more identifiable pill, or sold only to certain drugstores. These fortuities in no way diminish the culpability of a defendant for marketing the product, which is the basis of liability here.

Id. at 512, 541 N.Y.S.2d at 950, 539 N.E.2d at 1078.

On September 30, 1991, a group of plaintiffs, 1 comprising women allegedly injured by DES, along with their husbands, filed the instant suit in the Eastern District of New York against 33 manufacturers, or successors to manufacturers, of DES. The plaintiffs, who are New York or foreign residents, asserted jurisdiction on the basis of diversity of citizenship. The sole appellant, Boehringer, is a Delaware corporation authorized to do business in New York. Boehringer never sold or manufactured DES, but it is the successor to Stayner Corporation, which manufactured limited amounts of DES in Berkeley, California, between 1949 and 1971. Stayner sold products in California, Washington, Oregon, and Montana. It never marketed any products in New York, was not licensed to do business in New York, and had no significant contacts with New York. Stayner’s sales of DES were very small; the only years for which figures are available suggest that annual revenue from DES was about $5,000. In 1973, Stayner was acquired by Pharma-Investments, Ltd., a Canadian Corporation, and in 1979, Stayner was merged into Boehringer.

On October 25, 1991, Boehringer moved to dismiss for failure to state a claim and for lack of personal jurisdiction. Judge Wein-stein denied the motion in his April 13, 1992, opinion. He concluded (1) that the New York long arm statute reached Boehringer, 789 F.Supp. at 569-73, 591; (2) that this exercise of jurisdiction was constitutional, id. at 573-89, 591-92; (3) that New York would apply its law to Boehringer, id. at 566-68, 590-91; (4) that application of this choice of law rule was constitutional, id. at 568-69, *23 591; (5) that the complaint stated a claim against Boehringer under New York substantive law, id. at 589-90; and (6) that New York substantive DES law was constitutional, id. at 565-66.

Boehringer initially filed a notice of appeal on May 26, 1992. At that time no final judgment had been entered, and Boehringer voluntarily withdrew the appeal at the suggestion of staff counsel. On September 14, 1992, apparently at Boehringer’s request, the District Court entered a judgment that provides:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re: Eletson Holdings Inc.
S.D. New York, 2025
Tacon v. Cromwell
Second Circuit, 2025
Finney v. Howey
D. Alaska, 2022
In Re Paul J. DiPietro
Second Circuit, 2022
United States v. Carter
995 F.3d 1222 (Tenth Circuit, 2021)
Ou-Young v. Leavy
N.D. California, 2020
Lerner v. Satter
Second Circuit, 2019
Sexual Minorities Uganda v. Lively
899 F.3d 24 (First Circuit, 2018)
Am. Civil Liberties Union v. Dep't of Justice
894 F.3d 490 (Second Circuit, 2018)
SPV OSUS Ltd. v. UBS AG
Second Circuit, 2018
United States v. Fletcher Ex Rel. Fletcher
805 F.3d 596 (Fifth Circuit, 2015)
Terilli v. Commissioner of Internal Revenue
586 F. App'x 818 (Second Circuit, 2014)
Richard Ware Levitt, Esq. v. David H. Brooks
669 F.3d 100 (Second Circuit, 2012)
Daniel Conwill, IV v. Greenberg Traurig, L.L.P., E
448 F. App'x 434 (Fifth Circuit, 2011)
RSM Production Corp. v. Fridman
387 F. App'x 72 (Second Circuit, 2010)
Ward v. Santa Fe Independent School District
393 F.3d 599 (Fifth Circuit, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
7 F.3d 20, 1993 U.S. App. LEXIS 25692, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-des-litigation-deborah-ashley-and-andrew-ashley-v-boehringer-ca2-1993.